Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
7 rezultatima
The cardiovascular and subjective effects of thyrotropin releasing hormone (TRH) and a stable analogue, dimethyl proline-TRH, in healthy volunteers.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
1. The cardiovascular effects of TRH 0.5 mg and 1 mg and a stable TRH analogue, dimethylproline-TRH (RX77368) 1 mg, infused intravenously over 1 min were assessed in healthy volunteers in two randomised, double-blind, placebo controlled crossover studies. 2. Both doses of TRH produced significant
Pharmacological and electrophysiological properties of the naturally occurring Pro391Arg variant of the human 5-HT3A receptor.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
The 5-HT3A receptor, a ligand-gated ion channel, is involved in pain pathways, nausea and emesis, and irritable bowel syndrome, and may play a role in the pathogenesis of psychiatric diseases such as schizophrenia and depression. Recently, a naturally occurring variation (ProArg) in the second
Thyroid-stimulating hormone response to synthetic thyrotrophin releasing hormone in man.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Synthetic thyrotrophin-releasing hormone, L-pyroglutamyl-L-histidyl-L-proline-amide, has been administered intravenously to euthyroid subjects in doses ranging from 1 to 200 mug. Its effect was assessed by serial measurements of serum thyroid-stimulating hormone (T.S.H.). A rise in serum T.S.H. was
[Hydrocephalus in Paget's disease--a case report].
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
A case of Paget's disease in an elderly female who had a favourable evolution following ventriculoperitoneal (V-P) shunt is reported. On May 28, 1983, a 52-year-old female was transferred and admitted to us from the Dept. of Neurology because of headache in the occipital region and ataxic gait. On
Acute hyperglycemia is related to gastrointestinal symptoms in motion sickness: an experimental study.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Motion sickness is caused by exposure to unfamiliar motions and typical symptoms of motion sickness include nausea and vomiting. To observe the metabolic and hormonal differences between nausea/vomiting (NAV) subjects and non-nausea/vomiting (NNV) ones, and to understand how the differences in
First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
OBJECTIVE
AKT signaling is frequently deregulated in human cancers. MK-2206 is a potent, oral allosteric inhibitor of all AKT isoforms with antitumor activity in preclinical models. A phase I study of MK-2206 was conducted to investigate its safety, maximum-tolerated dose (MTD), pharmacokinetics
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
VS-6063 (also known as defactinib or PF-04554878) is a second-generation inhibitor of focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2). This phase I dose-escalation study was conducted in patients with advanced solid malignancies.
Using a traditional 3 + 3 design, VS-6063 was
Najkompletnija baza ljekovitog bilja potpomognuta znanošću
- Radi na 55 jezika
- Biljni lijekovi potpomognuti znanošću
- Prepoznavanje bilja slikom
- Interaktivna GPS karta - označite bilje na mjestu (uskoro)
- Pročitajte znanstvene publikacije povezane s vašom pretragom
- Pretražite ljekovito bilje po učincima
- Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Svi podaci temelje se na objavljenim znanstvenim istraživanjima
